Blood Biomarkers for Use in Alzheimer Disease—Moving From “If” to “How?”

Blood-based biomarkers have the potential to revolutionize clinical practice and clinical trials in Alzheimer disease (AD). However, to date, this “holy grail” opportunity has not been realized owing to a broad range of issues, including the lack of a clearly defined context of use (COU), lack of standardization of methods, and numerous failures at replication. Recently, however, a shift in the paradigm has occurred, with my colleagues and I proposing specific COUs for blood-based biomarkers along with potential paradigms for advancing from discovery to clinic and potential acceptable standards.1,2

See the full article on JAMA

Share to...

you may also be interested in …

Publications and Commentary from Briana Sprague

Publications and Commentary from Briana Sprague

Check out Briana Sprague’s recent publications and commentary she wrote for The Lancet Age- and time-varying associations between subjective health and episodic memory in older adults Chamberlain, J. D., Sprague, B. N., & Ross, L. A. (accepted). Age- and...